Cienfuegos, December 21 (RHC)-- The Cuban medication CIMAvax-EGF against advanced lung cancer has begun its final stage of clinical trials in the province of Cienfuegos.
Developed by the Havana-based Molecular Immunology Center, the Cuban vaccine is the first registered therapeutic treatment of its kind that generates antibodies against the patient's epidermal growth factor (EGF).
The antibodies generated by the drug inhibit and stop the proliferation of tumor cells, thus stabilizing the pathology, increasing survival and ostensibly improving the patients' quality of life.
Clinical trial lead researcher Yoana Herrera Leyva said that the aim is to assess the response of patients to high and normal doses of the vaccine, in order to customize the treatment.
Cuban Lung Cancer Vaccine Begins Final Stage of Clinical Trials
Artículos Relacionados
Comentarios
Deja un comentario
Todos los campos son requeridosMás Vistas
- Cuba condena atentado contra candidato presidencial estadounidense
- Cuba por primera vez a un Mundial de Atletismo Máster
- Presidente cubano envía mensaje a encuentro de alto nivel en China
- Ministerio de Salud de Belarús otorga registro a la vacuna cubana Cimavax
- Museo Nacional de Artes Decorativas presenta Flores de Austria